How long does calaspargase stay active in the body?
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study is checking how long the cancer drug calaspargase stays active in the body. It aims to help doctors understand how to best use this medicine for children and young adults with acute lymphoblastic leukemia or lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have acute lymphoblastic leukemia or lymphoma, and you are being treated by a pediatric hematology team.
- You are currently receiving a medicine called calaspargase as part of your treatment.
- You are 21 years old or younger.
- You are not taking part in another specific trial (AALL1732) that includes the drug inotuzumab.
- You are not pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how a chemotherapy drug called calaspargase pegol affects blood clotting in children and young adults with leukemia. It will help doctors understand if changes in clotting are common and safe.
This trial tests a combination of three drugs (calaspargase, decitabine, and venetoclax) for children, teens, and young adults with T-cell leukemia or lymphoma that has come back or not responded to treatment. The goal is to see if this combination can help destroy cancer cells.
This Phase 1/2 trial tests a combination of medicines (dasatinib, venetoclax, dexamethasone, cyclophosphamide, and cytarabine) in children and teens whose blood cancer has come back or did not respond to treatment. It aims to see whether this approach can control the cancer while checking what doses are safe.
This Phase 3 trial tests whether adding inotuzumab to standard post-induction chemotherapy improves outcomes for children and young teens with high-risk B-ALL, mixed phenotype acute leukemia (MPAL), or certain high-risk B-LLy. It may help by targeting leukemia cells more directly, but participation depends on specific age, lab results, and medical history rules.
This trial studies a treatment approach for children and teens newly diagnosed with lymphoblastic lymphoma. It may help doctors choose therapies based on genetic risk information from lab testing done on tumor samples.
This study follows how well a “pediatric-style” treatment plan works in teens and young adults with Ph-negative acute lymphoblastic leukemia (ALL) in real-world care. It mainly aims to understand outcomes and safety for patients who fit the specific leukemia and health criteria.
Hear when a new Childhood Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.